Webinar
Assessing Production and Stability for Current and Emerging Antibody Drug Conjugate Platforms
Summary
Clinically approved ADCs, despite high antibody sequence similarity, vary in linkers, payloads, and formulations. In this webinar we explore analytical techniques for ADC characterization—such as Intact Mass Spectrometry (DAR), peptide mapping, infrared spectroscopy, absorbance, DLS, and DSC—to evaluate structure, aggregation, and thermal stability.
Key experiments use Trastuzumab-based ADCs with different linker/payloads (DM1, MMAE, SN38) in clinically relevant buffers to assess how formulation affects stability and similarity. Emerging formats like dual-drug ADCs (ddADCs) are also examined.
Join us for this webinar to:
- Recognize formulation diversity in approved ADCs
- Review findings on formulation impact under short-term storage
- Learn key techniques for characterizing ADCs, including DAR, drug distribution, structure, and stability
Meet the Speaker
Associate Professor, Molecular Pharmaceutics;
Adjunct in Biomedical Engineering & Medicinal Chemistry, University of Utah
Shawn C. Owen, Ph.D is an Associate Professor in Molecular Pharmaceutics and Adjunct Professor in Biomedical Engineering and Medicinal Chemistry at the University of Utah. He is also a member of the Huntsman Cancer Institute Experimental Therapeutics Program. Dr. Owen’s research focuses on evaluating the pharmaceutic stability of antibody-based therapeutics, creating ADCs that induce self-amplifying therapeutic cascades, and engineering antibody-split enzyme systems for diagnostic and therapeutic applications. He has published ~45 research papers on drug delivery and biotechnology, and his research has produced 4 patents. Dr. Owen is recognized with several prominent university teaching awards and is sought for outreach workshops by both academic and industry sponsors.